Search
Logo
Subscribe
Login
Upgrade
Home
Research
SECSift↗
Guides ↗
Metrics ↗
SEC Terms ↗
Models↗
Logo
Search
Subscribe

Biotech

RVPH

+2

Aug 20, 2026

Teva's Fingerprints on Reviva

Reviva pushed its Phase 3 back a year, and the stock is down ~27% since my June write-up. Two developments matter more: (1) a patent filing that stretches exclusivity to 2046 and (2) evidence Teva has studied brilaroxazine since 2023.

RVPH

+2

Jun 18, 2026

Phase 3 Drug Priced for Zero

Reviva trades below its cash and just dropped to the OTC market, but it owns a schizophrenia drug that topped Caplyta's Phase 3 numbers, the kind big pharma buys for billions

Write-ups and models on asymmetric stocks and macro themes. Built on 10+ years studying top investors/funds, and 500,000+ words of published guides.

© 2026 StableBread.
beehiivPowered by beehiiv